# MY BONES MAY Break Easily

Please treat my bones with special care and do not exert force. My name is

I have hypophosphatasia (HPP), a rare genetic disease that causes me to have soft bones.

Symptoms of fractures are not always obvious; x-rays may not always indicate a fracture. I am on a treatment that replaces alkaline phosphatase (ALP) that may cause false positives on ALP tests. (*Read below for prescription details.*)

## STRENSIQ<sup>®</sup> (asfotase alfa) may affect other test results

It is important that you provide this card to any treating healthcare provider (HCP) as it contains information about lab test results.

STRENSIQ is a prescription medicine used to treat people with perinatal, infantile, and juvenile onset hypophosphatasia (HPP). Low levels of ALP are a hallmark of HPP. STRENSIQ works by replacing ALP.<sup>1</sup>

ALP is used as a detection reagent in many laboratory tests and the presence of STRENSIQ® in clinical laboratory samples could result in erroneous test results.<sup>1</sup>

HCPs should inform laboratory personnel that the patient is being treated with STRENSIQ and discuss use of an alternative testing platform, which does not use an ALP-based reagent for patients receiving STRENSIQ treatment.<sup>1</sup>

Serum ALP measurements are expected to be elevated during treatment with STRENSIQ and may be unreliable for clinical decision-making.<sup>1</sup>

HCPs should review additional information on Drug Interference with Laboratory Tests in the accompanying full Prescribing Information for STRENSIQ®.

Reference: 1. STRENSIQ®. Prescribing Information. Alexion Pharmaceuticals, Inc.

Please see full <u>Prescribing Information</u> and <u>Patient Information</u> for STRENSIQ (asfotase alfa), including Boxed WARNING regarding severe allergic (hypersensitivity) reactions.

My HPP specialist's name:\_\_\_\_\_

My HPP specialist's #:\_

Emergency contact:

Emergency contact #:

For more information, healthcare providers should call (888) 765-4747 or email medinfo@alexion.com.



Remember to update your Medical ID within your mobile device's health app to include your HPP information.

## STRENSIQ® (asfotase alfa) INDICATION & IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

## INDICATION

## What is STRENSIQ?

STRENSIQ is a prescription medicine used to treat people with perinatal, infantile, and juvenile onset hypophosphatasia (HPP).

## IMPORTANT SAFETY INFORMATION

## What is the most important information I should know about STRENSIQ?

STRENSIQ may cause serious side effects, including severe allergic (hypersensitivity) reactions. Allergic reactions are common with STRENSIQ treatment and can be severe and life-threatening. Severe allergic reactions have happened in some people within minutes after receiving STRENSIQ and more than 1 year after starting treatment with STRENSIQ. Stop using STRENSIQ and go to the nearest hospital emergency room right away if you or your loved one get any of the following signs and symptoms of a serious allergic reaction:

0

0

- difficulty breathing
- 0 choking sensation
  - swelling of your eyes, lips, or tongue
- feeling irritable chills 0 0

sweating

- dizziness
- nausea or vomiting
- fever 0
- headache
- skin redness skin rash or hives itching or numbness of the tongue, lips, cheeks, or gums

#### What are the other possible side effects of STRENSIQ? STRENSIQ may cause other serious side effects, including: skin thickening or pits at the injection site (lipodystrophy).

- Lipodystrophy is common and has happened after several months in people treated with STRENSIQ.
- calcium build-up in the eyes and kidneys. People with HPP are at increased risk for developing calcium build-up in the body. Calcium build-up in the eyes and kidneys has happened and is a common side effect of STRENSIQ. Calcium build-up in the eyes and kidneys may also happen in people with HPP who are not treated with STRENSIQ. Your healthcare provider should check your eyes and kidneys before and during treatment with STRENSIQ.
- immune-related effects. You may develop antibodies during treatment that may decrease how well STRENSIQ works. Tell your healthcare provider right away if you get worsening symptoms of HPP including: difficulty breathing, difficulty walking, feeling tired, bone pain, stiff joints, or loss of appetite.

The most common side effects of STRENSIQ include local skin injection site reactions such as skin redness, bruising, color change, pain, itching, hardening of the skin (induration), swelling, and bumps. These are not all the possible side effects of STRENSIQ. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects.

#### You will begin receiving STRENSIQ under the supervision of a healthcare provider. Tell your healthcare provider about all your medical conditions, including if you:

- have had an allergic reaction to STRENSIQ.
- . are pregnant or plan to become pregnant. It is not known if STRENSIQ will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if STRENSIQ passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if vou use STRENSIO.

## Tell your healthcare provider about all the medicines you take,

including prescription and over-the-counter medicines, vitamins, and herbal supplements.

There is a registry for people who use STRENSIQ. The purpose of this registry is to collect information about HPP and about what happens when you use STRENSIQ for a long time. For more information about this registry, talk with your healthcare provider or go to www.hppregistry.com

To report SUSPECTED SIDE EFFECTS, contact Alexion Pharmaceuticals, Inc. at 1-844-259-6783 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Please see full Prescribing Information and Patient Information for STRENSIQ (asfotase alfa), including Boxed WARNING regarding severe allergic (hypersensitivity) reactions.



ALEXION, the Alexion logo, and STRENSIQ are registered trademarks of Alexion Pharmaceuticals, Inc. © 2024, Alexion Pharmaceuticals, Inc. All rights reserved. US/STQ-H/0590 V1 07/2024